The PFS is a new method of administering Lucentis to treat people with wet age-related macular degeneration (AMD), macular edema after retinal vein occlusion (RVO) and myopic choroidal neovascularization (mCNV).
Genentech announced the Lucentis PFS was approved by the U.S. Food and Drug Administration (FDA) on Oct. 14, 2016, offering a ready-to-use option to deliver treatment. Genentech boasts that this is the first syringe prefilled with an anti-VEGF medicine FDA-approved to treat three different eye diseases—wet AMD, RVO and mCNV.
The press release from the October 2016 FDA approval is here. Lucentis 0.5 mg was recently FDA-approved as the first anti-VEGF medicine to treat patients with myopic CNV. With the Lucentis PFS, ophthalmologists now have a new treatment for this condition with a ready-to-use delivery method.